Is the FDA a Big Risk to This Company's Marijuana Plans?

Insys Therapeutics NASDAQ INSY 160 might have a problem on its hands This week the FDA requested that Endo International NASDAQ ENDP remove its opioid medication Opana ER from the market and that news raises the question Who s next If Insys Therapeutics